SCHEMBL12185486

SCHEMBL12185486

Cc1cc(Nc2ccc3[nH]c(C)cc3c2)nc(NCc2ccc3[nH]ccc3c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 1/20 0.48
MAPT P10636 11/20 0.47
LMNA P02545 6/20 0.47
KDM4E B2RXH2 6/20 0.47
HTT P42858 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
GPR55 Q9Y2T6 1/20 0.46
PLA2G1B P04054 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
SLC2A1 P11166 3/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43
KCNH2 Q12809 1/20 0.43
ABL1 P00519 1/20 0.42
SRC P12931 1/20 0.42
ALDH1A1 P00352 1/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12185799 0.87 EGFR (0.50) MAPTLMNAKDM4ESMN1; SMN2POLB
SCHEMBL12185296 0.84 EGFR (0.49) MAPTLMNAKDM4ESMN1; SMN2POLB
SCHEMBL12185440 0.82 ALPL (0.47) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL12185346 0.81 MAPT (0.39) DOT1LMAPTLMNAKDM4EHTT
SCHEMBL12185471 0.80 EGFR (0.47) MAPTKDM4ESMN1; SMN2POLBABL1
SCHEMBL12185320 0.79 MAPT (0.44) MAPTLMNAKDM4ESMN1; SMN2POLB
SCHEMBL12185332 0.79 MAPT (0.44) MAPTLMNAKDM4ESMN1; SMN2POLB
SCHEMBL14850419 0.78 SYK (0.49) MAPTLMNAKDM4ESMN1; SMN2POLB
SCHEMBL14850408 0.77 DOT1L (0.39) DOT1LMAPTLMNAKDM4EHTT
SCHEMBL12185480 0.76 EGFR (0.55) ABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571867-B1 NOVEL PYRIMIDINE DERIVATIVES NOVIGA RES AB (SE) 2015-11-04 EP disclosed
US-8927547-B2 Pyrimidine derivatives NOVIGA RESEARCH AB (SE) 2015-01-06 US disclosed
US-20130089518-A1 NOVEL PYRIMIDINE DERIVATIVES CHEMILIA AB (SE) 2013-04-11 US disclosed
WO-2011144742-A1 NOVEL PYRIMIDINE DERIVATIVES CHEMILIA AB (SE) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089518-A1 NOVEL PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP DOT1L 1084/4885MAPT 4203/4885LMNA 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.